Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer

This study is a prospective, single-arm, exploratory clinical research aimed at evaluating the efficacy and safety of lucetamab in combination with leucovorin in the conversion therapy of locally advanced potentially resectable EGFR mutation-positive non-small cell lung cancer, providing more robust clinical evidence for the improvement of treatment modalities for EGFR-mutated locally advanced NSCLC. At the same time, it seeks to identify biomarkers that can predict the therapeutic effect of the combination of lucetamab and leucovorin, offering more precise guidance for the selection of clinic

Trial Details

NCT ID
NCT07323056
Phase
PHASE2
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Sacituzumab Tirumotecan and Limertinib
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Sign the informed consent form
  • The age of the subjects is over 18 years old
  • Patients with non-small cell lung cancer (NSCLC) with EGFR mutation confirmed by pathology
  • Confirmed as locally advanced NSCLC (IIIA, IIIB, IIIC) by chest CT, PET-CT or/and EBUS, and MDT discussion concludes that immediate local surgery i…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →